New biologic therapy for systemic lupus erythematosus

Current Opinion in Pharmacology

Volumn 13, Issue 3, 2013, Pages 405-412

  Ding, Hui Jen ^a,b   Gordon, Caroline ^a,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PUTRAJAYA HOSPITAL   (Malaysia)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ALPHA INTERFERON; AMG 557; AMG 811; AUTOANTIBODY; BELIMUMAB; BIOLOGICAL PRODUCT; BLISIBIMOD; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYTOKINE; EDRATIDE; EPRATUZUMAB; FONTOLIZUMAB; FORIGERIMOD; INFLIXIMAB; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PLACEBO; RITUXIMAB; RONTALIZUMAB; SBI 087; SIFALIMUMAB; SIRUKUMAB; TABALUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTHRITIS; B LYMPHOCYTE; BIOLOGICAL THERAPY; CENTRAL NERVOUS SYSTEM LUPUS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; LEUKOENCEPHALOPATHY; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS VULGARIS; MORBIDITY; MORTALITY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; POLYARTHRITIS; PRIORITY JOURNAL; PROTEIN DEFECT; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 84879107691     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.04.005     Document Type: Review

References (52)

1. V. Marian, and J.H. Anolik Treatment targets in systemic lupus erythematosus: biology and clinical perspective Arthritis Res Ther 14 Suppl 4 2012 S3 10.1186/ar3917
2. C. Yildirim-Toruner, and B. Diamond Current and novel therapeutics in the treatment of systemic lupus erythematosus J Allergy Clin Immunol 127 2011 303 312
3. S.A. Apostolidis, L.A. Lieberman, K. Kis-Toth, J.C. Crispín, and G.C. Tsokos The dysregulation of cytokine networks in systemic lupus erythematosus J Interferon Cytokine Res 31 2011 769 779
4. C.S. Yee, K. McElhone, L.S. Teh, and C. Gordon Assessment of disease activity and quality of life in systemic lupus erythematosus - new aspects Best Pract Res Clin Rheumatol 23 2009 457 467
5. R.A. Furie, M.A. Petri, D.J. Wallace, E.M. Ginzler, J.T. Merrill, W. Stohl, W.W. Chatham, V. Strand, A. Weinstein, and M.R. Chevrier Novel evidence-based systemic lupus erythematosus responder index Arthritis Rheum 61 2009 1143 1151
6. S.V. Navarra, R.M. Guzmán, A.E. Gallacher, S. Hall, R.A. Levy, R.E. Jimenez, E.K. Li, M. Thomas, H.Y. Kim, and M.G. León Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 721 731
7. R. Furie, M. Petri, O. Zamani, R. Cervera, D.J. Wallace, D. Tegzová, J. Sanchez-Guerrero, A. Schwarting, J.T. Merrill, and W.W. Chatham A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis Rheum 63 2011 3918 3930
8. L. Lan, F. Han, and J.H. Chen Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis J Zhejiang Univ Sci B 13 2012 731 744
9. J.T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, D.J. Wallace, S.C. Bae, L. Sigal, J.C. Becker, and S. Kelly The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial Arthritis Rheum 62 2010 3077 3087
10. D. Wofsy, J.L. Hillson, and B. Diamond Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions Arthritis Rheum 64 2012 3660 3665
11. M. Petri, W. Stohl, W. Chatham, W.J. McCune, M. Chevrier, J. Ryel, V. Recta, J. Zhong, and W. Freimuth Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus Arthritis Rheum 58 2008 2453 2459
12. S. Manzi, J. Sánchez-Guerrero, J.T. Merrill, R. Furie, D. Gladman, S.V. Navarra, E.M. Ginzler, D.P. D'Cruz, A. Doria, and S. Cooper Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials Ann Rheum Dis 71 2012 1833 1838
13. R.F. van Vollenhoven, M.A. Petri, R. Cervera, D.A. Roth, B.N. Ji, C.S. Kleoudis, Z.J. Zhong, and W. Freimuth Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response Ann Rheum Dis 71 2012 1343 1349
14. G. Murdaca, B.M. Colombo, and F. Puppo Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events Autoimmun Rev 11 2011 56 60
15. C. Favas, and D. Isenberg B-cell depletion therapy in SLE - what are the current prospects for its acceptance? Nat Rev Rheumatol 5 2009 711 716
16. E.M. Vital, S. Dass, M.H. Buch, K. Henshaw, C.T. Pease, M.F. Martin, F. Ponchel, A.C. Rawstron, and P. Emery B cell biomarkers of rituximab responses in systemic lupus erythematosus Arthritis Rheum 63 2011 3038 3047
17. T.Y. Lu, K.P. Ng, G. Cambridge, M.J. Leandro, J.C. Edwards, M. Ehrenstein, and D.A. Isenberg A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients Arthritis Rheum 61 2009 482 487
18. I. Gunnarsson, B. Sundelin, T. Jónsdóttir, S.H. Jacobson, E.W. Henriksson, and R.F. van Vollenhoven Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis Arthritis Rheum 56 2007 1263 1272
19. J.A. Reynolds, V. Toescu, C.S. Yee, A. Prabu, D. Situnayake, and C. Gordon Effects of rituximab on resistant SLE disease including lung involvement Lupus 18 2009 67 73
20. M. Ramos-Casals, M.J. Soto, M.J. Cuadrado, and M.A. Khamashta Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases Lupus 18 2009 767 776
21. B. Terrier, Z. Amoura, P. Ravaud, E. Hachulla, R. Jouenne, B. Combe, C. Bonnet, P. Cacoub, A. Cantagrel, and M. de Bandt Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry Arthritis Rheum 62 2010 2458 2466
22. T. Turner-Stokes, T.Y. Lu, M.R. Ehrenstein, I. Giles, A. Rahman, and D.A. Isenberg The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation Rheumatology (Oxford) 50 2011 1401 1408
23. M. Weidenbusch, C. Römmele, A. Schröttle, and H.J. Anders Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis Nephrol Dial Transplant 28 2013 106 111
24. J.T. Merrill, C.M. Neuwelt, D.J. Wallace, J.C. Shanahan, K.M. Latinis, J.C. Oates, T.O. Utset, C. Gordon, D.A. Isenberg, and H.J. Hsieh Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 62 2010 222 233
25. B.H. Rovin, R. Furie, K. Latinis, R.J. Looney, F.C. Fervenza, J. Sanchez-Guerrero, R. Maciuca, D. Zhang, J.P. Garg, and P. Brunetta Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum 64 2012 1215 1226
26. E. Palazzo, and S.A. Yahia Progressive multifocal leukoencephalopathy in autoimmune diseases Joint Bone Spine 79 2012 351 355
27. A. Rahman, and D.A. Isenberg Systemic lupus erythematosus N Engl J Med 358 2008 929 939
28. C. Daridon, D. Blassfeld, K. Reiter, H.E. Mei, C. Giesecke, D.M. Goldenberg, A. Hansen, A. Hostmann, D. Frölich, and T. Dörner Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus Arthritis Res Ther 12 2010 R204 10.1186/ar3179
29. T. Dörner, J. Kaufmann, W.A. Wegener, N. Teoh, D.M. Goldenberg, and G.R. Burmester Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus Arthritis Res Ther 8 2006 R74 10.1186/ar1942
30. P. Traczewski, and L. Rudnicka Treatment of systemic lupus erythematosus with epratuzumab Br J Clin Pharmacol 71 2011 175 182
31. D.J. Wallace, K. Kalunian, M. Petri, V. Strand, F. Houssiau, M. Pike, B. Kilgallen, S. Bongardt, A. Barry, and L. Kelley Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomized, double-blind, placebo-controlled, multicenter study Ann Rheum Dis 2013 10.1136/annrheumdis- 2012-202760
32. W. Stohl Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep 14 2012 303 309 10.1007/s11926-012-0254-256
33. M. Dall'Era, E. Chakravarty, D. Wallace, M. Genovese, M. Weisman, A. Kavanaugh, K. Kalunian, P. Dhar, E. Vincent, and C. Pena-Rossi Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial Arthritis Rheum 56 2007 4142 4150
34. E.M. Ginzler, S. Wax, A. Rajeswaran, S. Copt, J. Hillson, E. Ramos, and N.G. Singer Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial Arthritis Res Ther 14 2012 R33 10.1186/ar3738
35. P.K. Chugh Lupus: novel therapies in clinical development Eur J Int Med 23 2012 212 218
36. R. Zimmer, H.R. Scherbarth, O.L. Rillo, J.J. Gomez-Reino, and S. Muller Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial Ann Rheum Dis 2012 10.1136/annrheumdis-2012-202460
37. S. Muller, F. Monneaux, N. Schall, R.K. Rashkov, B.A. Oparanov, P. Wiesel, J.M. Geiger, and R. Zimmer Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial Arthritis Rheum 58 2008 3873 3883
38. N. Schall, N. Page, C. Macri, O. Chaloin, J.P. Briand, and S. Muller Peptide-based approaches to treat lupus and other autoimmune diseases J Autommun 39 2012 143 153
39. W. Xiong, and R.G. Lahita Novel treatments for systemic lupus erythematosus Ther Adv Musculoskelet Dis 3 2011 255 266
40. N. Jacob, and W. Stohl Cytokine disturbances in systemic lupus erythematosus Arthritis Res Ther 13 2011 228 10.1186/ar3349
41. B.D. Poole, T.B. Niewold, and G.C. Tsokos Cytokines in systemic lupus erythematosus J Biomed Biotechnol 2012 427824 10.1155/2012/427824
42. G.G. Illei, Y. Shirota, C.H. Yarboro, J. Daruwalla, E. Tackey, K. Takada, T. Fleisher, J.E. Balow, and P.E. Lipsky Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Arthritis Rheum 62 2010 542 552
43. T.B. Niewold, D.N. Clark, R. Salloum, and B.D. Poole Interferon alpha in systemic lupus erythematosus J Biomed Biotechnol 2010 10.1155/2010/948364 Article ID 948364
44. B. Yan, S. Ye, G. Chen, M. Kuang, N. Shen, and S. Chen Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells Arthritis Rheum 58 2008 801 812
45. B.W. Higgs, Z. Liu, B. White, W. Zhu, W.I. White, C. Morehouse, P. Brohawn, P.A. Kiener, L. Richman, and D. Fiorentino Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway Ann Rheum Dis 70 2011 2029 2036
46. E.I. Lichtman, S.M. Helfgott, and M.A. Kriegel Emerging therapies for systemic lupus erythematosus - focus on targeting interferon-alpha Clin Immunol 143 2012 210 221
47. W.A. Sifuentes Giraldo, M.J. García Villanueva, A.L. Boteanu, A. Lois Iglesias, and A.C. Zea Mendoza New targets in systemic lupus (part 1/2) Reumatol Clin 8 2012 263 269
48. J.T. Merrill, D.J. Wallace, M. Petri, K.A. Kirou, Y. Yao, W.I. White, R. Robbie, R. Levin, S.M. Berney, and V. Chindalore Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study Ann Rheum Dis 70 2011 1905 1913
49. J.M. McBride, J. Jiang, A.R. Abbas, A. Morimoto, J. Li, R. Maciuca, M. Townsend, D.J. Wallace, W.P. Kennedy, and J. Drappa Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study Arthritis Rheum 64 2012 3666 3676
50. B.R. Lauwerys, E. Hachulla, F. Spertini, E. Lazaro, C. Jorgensen, X. Mariette, E. Haelterman, G. Grouard-Vogel, B. Fanget, and O. Dhellin Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with Interferon alpha-Kinoid Arthritis Rheum 2012 10.1002/art.37785
51. M. Aringer, F. Houssiau, C. Gordon, W.B. Graninger, R.E. Voll, E. Rath, G. Steiner, and J.S. Smolen Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients Rheumatology (Oxford) 48 2009 1451 1454
52. S.S. Uppal, S.J. Hayat, and R. Raghupathy Efficacy and safety of infliximab in active SLE: a pilot study Lupus 18 2009 690 697